Automate Your Wheel Strategy on DXCM
With Tiblio's Option Bot, you can configure your own wheel strategy including DXCM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DXCM
- Rev/Share 11.5467
- Book/Share 6.9703
- PB 7.8676
- Debt/Equity 0.9248
- CurrentRatio 1.5646
- ROIC 0.1083
- MktCap 21452871665.0
- FreeCF/Share 2.7152
- PFCF 20.2023
- PE 29.7599
- Debt/Assets 0.3361
- DivYield 0
- ROE 0.2982
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | DXCM | Stifel | -- | Buy | -- | $85 | Oct. 21, 2025 |
| Downgrade | DXCM | Oppenheimer | Outperform | Perform | -- | -- | Sept. 8, 2025 |
| Initiation | DXCM | Argus | -- | Buy | -- | $100 | Aug. 21, 2025 |
| Initiation | DXCM | Truist | -- | Buy | -- | $102 | June 16, 2025 |
| Initiation | DXCM | Goldman | -- | Buy | -- | $104 | May 30, 2025 |
| Initiation | DXCM | Mizuho | -- | Outperform | -- | $85 | April 10, 2025 |
| Upgrade | DXCM | Redburn Atlantic | Neutral | Buy | $85 | $115 | Feb. 3, 2025 |
| Upgrade | DXCM | Robert W. Baird | Neutral | Outperform | $86 | $104 | Jan. 16, 2025 |
News
Here's Why You Should Hold DexCom Stock in Your Portfolio for Now
Published: November 11, 2025 by: Zacks Investment Research
Sentiment: Positive
DXCM's strong Q3 growth, expanding CGM coverage and innovation-driven momentum position it for sustained adoption despite rising competition.
Read More
DXCM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that DexCom, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: November 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against DexCom, Inc. (“DexCom” or “the Company”) (NASDAQ: DXCM) and certain of its officers.
Read More
Shareholders who lost money in shares of DexCom, Inc. (NASDAQ: DXCM) Should Contact Wolf Haldenstein Immediately
Published: November 11, 2025 by: PRNewsWire
Sentiment: Neutral
Lead Plaintiff Deadline is December 26, 2025 NEW YORK , Nov. 11, 2025 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a federal securities class action lawsuit has been filed against DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM) and certain of its officers for alleged violations of federal securities laws. PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION Class Period: July 26, 2024 – September 17, 2025 (inclusive) The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and failed to disclose that: DexCom made material design …
Read More
DexCom, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before December 26, 2025 to Discuss Your Rights – DXCM
Published: November 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM).
Read More
Shareholders who lost money in shares of DexCom, Inc. (NASDAQ: DXCM) Should Contact Wolf Haldenstein Immediately
Published: November 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a federal securities class action lawsuit has been filed against DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) and certain of its officers for alleged violations of federal securities laws. PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION Class Period: July 26, 2024 – September 17, 2025 (inclusive) The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and failed to disclose that: DexCom made material design changes to its G6 and G7 continuous …
Read More
Lowey Dannenberg Notifies DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
Published: November 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) for violations of the federal securities laws on behalf of investors who purchased or acquired DexCom securities between July 26, 2024 and September 17, 2025, inclusive (the “Class Period”).
Read More
DXCM Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges DXCM Investors with Losses to Contact the Firm
Published: November 07, 2025 by: PRNewsWire
Sentiment: Neutral
RADNOR, Pa. , Nov. 7, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against DexCom, Inc. ("DexCom") (NASDAQ: DXCM) on behalf of those who purchased or otherwise acquired DexCom securities between July 26, 2024, and September 17, 2025, inclusive (the "Class Period").
Read More
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: November 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 07, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DexCom, Inc. (“DexCom” or “the Company”) (NASDAQ: DXCM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 26, 2024 and September 17, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before December 26, 2025.
Read More
Class Action Announcement for DexCom, Inc. (DXCM): Kessler Topaz Meltzer & Check, LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against DexCom, Inc.
Published: November 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
RADNOR, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against DexCom, Inc. (“DexCom”) (NASDAQ: DXCM) on behalf of those who purchased or otherwise acquired DexCom securities between July 26, 2024, and September 17, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is December 26, 2025.
Read More
Portnoy Law Firm Announces Class Action on Behalf of DexCom, Inc. Investors
Published: November 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises DexCom, Inc., (“DexCom” or the "Company") (NASDAQ: DXCM) investors off a class action on behalf of investors that bought securities between July 26, 2024 and September 17, 2025, inclusive (the “Class Period”). DexCom investors have until December 26, 2025 to file a lead plaintiff motion.
Read More
From Dividends to Growth: Why These 3 Stocks Stand Out in 2025
Published: November 06, 2025 by: MarketBeat
Sentiment: Positive
It's rare for an attractive dividend stock also to have growth potential. Most leading dividend distributors have moved past their high-growth days and have transitioned into stable, mature businesses, exhibiting fairly steady performance from quarter to quarter.
Read More
DEXCOM CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds DXCM Investors of the December 26th Deadline in Filed Class Action Lawsuit
Published: November 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In DexCom (DXCM) To Contact Him Directly To Discuss Their Options If you purchased or acquired DexCom securities between July 26, 2024 and September 17, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Read More
DXCM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that DexCom, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: November 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against DexCom, Inc. (“DexCom” or “the Company”) (NASDAQ: DXCM) and certain of its officers.
Read More
ROSEN, A LEADING LAW FIRM, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DXCM
Published: November 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between July 26, 2024 and September 17, 2025, both dates inclusive (the “Class Period”) of the important December 29, 2025 lead plaintiff deadline.
Read More
Here's Why DexCom (DXCM) is a Strong Growth Stock
Published: November 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: November 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DexCom, Inc. (“DexCom” or “the Company”) (NASDAQ: DXCM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 26, 2024 and September 17, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before December 26, 2025.
Read More
Is Dexcom Stock A Buy Now?
Published: November 03, 2025 by: Forbes
Sentiment: Neutral
DexCom (DXCM) stock ought to be included on your watchlist. Here is why – it is presently trading within the support range ($55.31 – $61.13), levels from which it has bounced significantly in the past.
Read More
DexCom Stock Falls Despite Q3 Earnings Beat, 2025 Revenue View Raised
Published: October 31, 2025 by: Zacks Investment Research
Sentiment: Positive
DXCM posts double-digit Q3 growth and raises 2025 revenue outlook, but shares tumble despite strong CGM momentum and innovation updates.
Read More
DXCM Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against DexCom, Inc.
Published: October 31, 2025 by: Business Wire
Sentiment: Neutral
RADNOR, Pa.--(BUSINESS WIRE)-- #classaction--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against DexCom, Inc. (“DexCom”) (NASDAQ: DXCM) on behalf of those who purchased or otherwise acquired DexCom securities between July 26, 2024, and September 17, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is December 26, 2025. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered DexCom losses,.
Read More
DXCM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that DexCom, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: October 31, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Oct. 31, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against DexCom, Inc. ("DexCom" or "the Company") (NASDAQ: DXCM) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired DexCom securities between July 26, 2024 and September 17, 2025, both dates inclusive (the "Class Period").
Read More
Shareholders who lost money in shares of DexCom, Inc. (NASDAQ: DXCM) Should Contact Wolf Haldenstein Immediately
Published: October 31, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a federal securities class action lawsuit has been filed against DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) and certain of its officers for alleged violations of federal securities laws. PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION Class Period: July 26, 2024 – September 17, 2025 (inclusive) The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and failed to disclose that: DexCom made material design changes to its G6 and G7 continuous …
Read More
DexCom Stock Is the Worst Performer in the S&P 500. Here's Why.
Published: October 31, 2025 by: Barrons
Sentiment: Negative
The maker of diabetes technology posts better-than-expected revenue but shares are falling.
Read More
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit
Published: October 28, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between July 26, 2024 and September 17, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.
Read More
Rosen Law Firm Urges DexCom, Inc. (NASDAQ: DXCM) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Published: October 28, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of DexCom, Inc. (NASDAQ: DXCM) securities between July 26, 2024 and September 17, 2025, both dates inclusive (the “Class Period”). DexCom is a medical device company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Alleg.
Read More
Portnoy Law Firm Announces Class Action on Behalf of DexCom, Inc. Investors
Published: October 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Oct. 28, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises DexCom, Inc., (“DexCom” or the "Company") (NASDAQ: DXCM) investors off a class action on behalf of investors that bought securities between July 26, 2024 and September 17, 2025, inclusive (the “Class Period”). DexCom investors have until December 26, 2025 to file a lead plaintiff motion.
Read More
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed DexCom, Inc. (DXCM)
Published: October 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) securities between July 26, 2024 and September 17, 2025, inclusive (the “Class Period”).
Read More
Can Dexcom Deliver Strong Q3 Earnings on Stelo Gains and G7 Adoption?
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Positive
DXCM's Q3 results are likely to benefit from rising G7 use, early Stelo traction and expanding access across Type 2 diabetes markets.
Read More
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of DexCom, Inc. (DXCM) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
Published: October 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, Oct. 28, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information, including allegations that: (i) DexCom had made material design changes to the G6 and G7 unauthorized by the United States Food and Drug Administration (the "FDA"); (ii) the foregoing design changes rendered the G6 and G7 less reliable than their prior iterations, presenting a material health risk to users relying on those devices for accurate glucose readings; (iii) …
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DexCom, Inc. - DXCM
Published: October 23, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Oct. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DexCom, Inc. - DXCM
Published: October 13, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Oct. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
About DexCom, Inc. (DXCM)
- IPO Date 2005-04-14
- Website https://www.dexcom.com
- Industry Medical - Devices
- CEO Kevin Ronald Sayer
- Employees 10200